Compare · GILD vs SOPH
GILD vs SOPH
Side-by-side comparison of Gilead Sciences Inc. (GILD) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 250.5x SOPH ($736.4M).
- Over the past year, GILD is up 29.9% and SOPH is up 154.9% - SOPH leads by 125.0 points.
- SOPH has been more active in the news (14 items in the past 4 weeks vs 12 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 14 for SOPH).
- Company
- Gilead Sciences Inc.
- SOPHiA GENETICS SA
- Price
- $149.01+0.15%
- $8.54-1.16%
- Market cap
- $184.47B
- $736.4M
- 1M return
- +10.91%
- +53.05%
- 1Y return
- +29.89%
- +154.93%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 12
- 14
- Recent ratings
- 25
- 14
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SOPH
- SEC Form 144 filed by SOPHiA GENETICS SA
- Chief People Officer Valente Manuela exercised 10,000 units of Ordinary Shares at a strike of $3.20 and sold $79,439 worth of Ordinary Shares (10,000 units at $7.94) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $163,482 worth of Ordinary Shares (20,000 units at $8.17) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,887 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $30,076 worth of Ordinary Shares (4,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 586,887 units (SEC Form 4)
- Chief Medical Officer Menu Philippe sold $37,580 worth of Ordinary Shares (5,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 218,387 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $209,209 worth of Ordinary Shares (28,500 units at $7.34) as part of a pre-agreed trading plan, decreasing direct ownership by 0.82% to 3,444,322 units (SEC Form 4)
- Chief Technology Officer Verma Abhimanyu sold $38,000 worth of Ordinary Shares (5,000 units at $7.60) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 182,171 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu exercised 10,000 units of Ordinary Shares at a strike of $3.28 and sold $144,924 worth of Ordinary Shares (20,000 units at $7.25) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 590,887 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $138,412 worth of Ordinary Shares (20,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 0.57% to 3,472,822 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $69,168 worth of Ordinary Shares (10,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 600,887 units (SEC Form 4)